Merus N.V. (MRUS) is a clinical-stage biotechnology company that develops innovative cancer therapeutics. The company's proprietary technology platform is based on the discovery of full-length human antibodies, called Biclonics, that are capable of simultaneously binding two different targets. Merus is currently developing a pipeline of Biclonics-based product candidates for the treatment of various cancers, including solid tumors and hematological malignancies. The company's lead candidate, Zenocutuzumab, is being evaluated in clinical trials for the treatment of tumors that harbor NRG1 fusions, which are present in various types of cancers. Merus is also collaborating with several pharmaceutical companies, including Incyte Corporation, to develop and commercialize Biclonics-based therapies.
Merus N.V. (MRUS) is a clinical-stage biotechnology company that develops innovative cancer therapeutics. The company's proprietary technology platform is based on the discovery of full-length human antibodies, called Biclonics, that are capable of simultaneously binding two different targets. Merus is currently developing a pipeline of Biclonics-based product candidates for the treatment of various cancers, including solid tumors and hematological malignancies. The company's lead candidate, Zenocutuzumab, is being evaluated in clinical trials for the treatment of tumors that harbor NRG1 fusions, which are present in various types of cancers. Merus is also collaborating with several pharmaceutical companies, including Incyte Corporation, to develop and commercialize Biclonics-based therapies.